SCHEMBL17137754

SCHEMBL17137754

Fc1ccccc1COc1cccc(-c2ccc3[nH]cnc3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.49
F9 P00740 1/20 0.47
PARP15 Q460N3 1/20 0.43
PARP10 Q53GL7 1/20 0.43
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
MAOB P27338 4/20 0.42
QPCT Q16769 1/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
IGF1R P08069 1/20 0.39
HPD P32754 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30450179 0.86 EGLN1 (0.48) F9LMNAQPCTNPC1RAB9A
SCHEMBL17137719 0.86 EGLN1 (0.48) F9LMNAQPCTNPC1RAB9A
SCHEMBL17137751 0.81 MAOB (0.50) F9MAOBPRMT5
SCHEMBL30450030 0.77 EGLN1 (0.48) F9HTTMAOBSMN1; SMN2MAPK1
SCHEMBL17137537 0.77 EGLN1 (0.48) F9HTTMAOBSMN1; SMN2MAPK1
SCHEMBL30450790 0.76 EGLN1 (0.48) F9MAOB
SCHEMBL17137741 0.76 EGLN1 (0.48) F9MAOB
SCHEMBL2096521 0.75 MMP12 (0.55) LMNATSHRQPCTMAPK1
SCHEMBL2096516 0.75 QPCT (0.42) KDM4EQPCTRECQLTDP1PRMT5
SCHEMBL17137714 0.74 IP6K1 (0.44) QPCTPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 EGFR 4375/4885F9 3430/4885PARP15 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.